HBV replication inhibitors

Rouvière, Claire Pierra; Dousson, Cyril B.; Tavis, John E.

doi:10.1016/j.antiviral.2020.104815

Cited by 44 publications

(37 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase II NCT:03891420 [193] Remdesivir Antiviral Phase III NCT:04292730 [194] Levovir Antiviral Phase II NCT:04347915 [195] Emtricitabine + Tenofovir Non-nucleoside reverse transcriptase inhibitor + Nucleotide reverse transcriptase inhibitor This drug class is widely recommended as first-line treatment for HIV when co-administered with two nucleoside or nucleotide reverse transcriptase inhibitors. These drugs compete with deoxycytidine 5'-triphosphate for reverse transcriptase enzyme.…”

Section: Antiviralmentioning

confidence: 99%

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

Ramarao

Joshi

Jagadeesh³

2020

Cellular Signalling

129

107

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection. It does so by binding to host cell angiotensin converting enzyme 2 (ACE2) receptors, leading to endocytosis with the receptor, and subsequently using the host cell's machinery to replicate copies of itself and invade new cells. The extent of the spread of infection in the body is dependent on the pattern of ACE2 expression and overreaction of the immune system. Additionally, by inducing an imbalance in the renin-angiotensin-aldosterone system (RAAS) and the loss of ACE2 would favour the progression of inflammatory and thrombotic processes in the lungs. No drug or vaccine has yet been approved to treat human coronaviruses. Hundreds of clinical trials on existing approved drugs from different classes acting on a multitude of targets in the virus life cycle are ongoing to examine potential effectiveness for the prevention and treatment of the infection. This review summarizes the SARS-CoV-2 virus life cycle in the host cell and provides a biological and pathological point of view for repurposed and experimental drugs for this novel coronavirus. The viral life cycle provides potential targets for drug therapy.

show abstract

Section: Antiviralmentioning

confidence: 99%

Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19

Ramarao

Joshi

Jagadeesh³

2020

Cellular Signalling

129

107

View full text Add to dashboard Cite

show abstract

“…NAs suppress viremia at clinically undetectable levels in up to 76% of HBeAg (+) and 93% of HBeAg (−) patients after one year of treatment. Efficacy can vary in patients with different HBV genotypes [ 73 , 74 ]. Although some HBeAg (−) patients can discontinue treatment with NAs, their use is essentially life-long for the large majority of patients.…”

Section: Current Therapiesmentioning

confidence: 99%

“…However, virological relapse almost always occurs. Eight NAs have been approved against the HBV, of which the current recommended ones are entecavir and the two tenofovir prodrugs, disoproxil and alafenamide [ 73 ].…”

Section: Current Therapiesmentioning

confidence: 99%

“…The first approved NA which was effective against HBV was lamivudine (3TC, LMV, Epivir © , Zeffix © , Heptodin © , Hepitec © ). It was approved in the United States of America in 1998 [ 73 ], and it is administered once daily, with few side effects. It is no longer widely used because it is less potent than newer drugs and most patients develop resistance within one to five years [ 65 ].…”

Section: Current Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Hepatitis B Treatment

et al. 2021

View full text Add to dashboard Cite

Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells. Thus, achieving a “functional cure” of the infection remains a real challenge. Recent findings concerning the viral replication cycle have led to development of novel therapeutic approaches including viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, ribonuclease H inhibitors, and capsid assembly modulators. Promising preclinical results have been obtained, and the leading molecules under development have entered clinical evaluation. This review summarizes the key steps of the HBV life cycle, examines the currently approved anti-HBV drugs, and analyzes novel HBV treatment regimens.

show abstract

“…A way to further reduce toxicity would therefore be to strictly deliver and/or activate the NA in the target cell type (hepatocytes in the case of HBV). 16 In the current issue of Journal of Hepatology, Higashi-Kuwata and colleagues 17 describe a novel nucleoside analogue with very potent and long-lasting anti-HBV activity. This NA, called E-CFCP (chemical name: (1S,3S,5S,E)-3-(2-amino-6-oxo-1,6-dihydro-9Hpurin-9-yl)-2-(fluoromethylene)-5-hydroxy-1-(hydro-xymethyl) cyclo-pentane-1-carbonitrile), is a guanosine analogue derived from 4'-cyano-methylene-carbocyclic-2'-deoxyguanosine (CMCdG) and has a structure similar to ETV.…”

Section: Improvements To Currently Used Nas?mentioning

confidence: 99%